Poseida Therapeutics(PSTX) - 2021 Q2 - Quarterly Report

Revenue Generation - The company has not generated any revenue from product sales and does not expect to do so until at least several years after obtaining regulatory approval for its product candidates [89][99]. Funding and Grants - The company has received a total of $19.7 million from a $19.8 million grant from the California Institute of Regenerative Medicine (CIRM) to support the clinical trial for P-BCMA-101 [102]. - The company expects to finance its operations through equity offerings, debt financings, or other capital sources until it can generate substantial product revenue [99]. Research and Development - The company is advancing multiple CAR-T product candidates in clinical phases, including P-BCMA-101 and P-PSMA-101, targeting relapsed/refractory multiple myeloma and metastatic castrate-resistant prostate cancer, respectively [93][94]. - The company anticipates significant increases in research and development expenses as it continues to develop its product candidates and seek regulatory approvals [98][108]. - The company is developing a fully allogeneic CAR-T product candidate, P-BCMA-ALLO1, with an IND filing and Phase 1 clinical trial initiation expected in Q3 2021 [94]. - The company is utilizing its proprietary piggyBac DNA Delivery System and Cas-CLOVER Site-specific Gene Editing System for manufacturing its product candidates [92][95]. - The company plans to file an IND and initiate a Phase 1 clinical trial for at least one dual CAR program in 2022 [96]. - The company is evaluating the potential modification of the P-OTC-101 program to utilize a fully non-viral nanoparticle delivery system, which could impact timelines [100]. Financial Performance - Research and development expenses increased to $36.0 million for the three months ended June 30, 2021, up from $25.2 million in the same period of 2020, representing a $10.8 million increase [114]. - General and administrative expenses rose to $8.9 million for the three months ended June 30, 2021, compared to $4.2 million in the same period of 2020, an increase of $4.6 million [117]. - The net loss for the three months ended June 30, 2021, was $45.7 million, compared to a net loss of $30.4 million for the same period in 2020, reflecting an increase of $15.3 million [114]. - For the six months ended June 30, 2021, research and development expenses totaled $65.1 million, up from $48.6 million in the same period of 2020, marking a $16.5 million increase [123]. - General and administrative expenses for the six months ended June 30, 2021, were $17.2 million, compared to $9.1 million for the same period in 2020, an increase of $8.2 million [124]. - The company incurred a net loss of $84.0 million for the six months ended June 30, 2021, compared to a net loss of $59.2 million for the same period in 2020, an increase of $24.8 million [120]. - As of June 30, 2021, the company had an accumulated deficit of $365.9 million [127]. Cash and Liquidity - Cash, cash equivalents, and short-term investments as of June 30, 2021, were $237.3 million, expected to fund operations for at least the next twelve months [129]. - As of June 30, 2021, the company had cash, cash equivalents, and short-term investments totaling $237.3 million, indicating a strong liquidity position [151]. - For the six months ended June 30, 2021, net cash used in operating activities was $70.1 million, compared to $53.7 million in the same period of 2020, reflecting an increase in cash outflow of approximately 30.5% [135][136]. - Cash provided by investing activities significantly increased to $185.4 million in the first half of 2021, up from $5.7 million in 2020, primarily due to proceeds from maturities of short-term investments [137][138]. - Cash provided by financing activities decreased to $0.4 million in the first half of 2021 from $107.4 million in 2020, which included substantial proceeds from the sale of Series D preferred stock in the prior year [140]. Interest and Expenses - Interest expense for the three months ended June 30, 2021, was $0.8 million, a slight decrease from $0.9 million in the same period of 2020 [118]. - Interest expense for the six months ended June 30, 2021, was $1.7 million, compared to $1.8 million for the same period in 2020 [125]. - Non-cash expenses for the first half of 2021 included $8.2 million in stock-based compensation and $2.2 million in depreciation and amortization [135]. Obligations and Regulations - The company has contractual obligations related to research and development, clinical trials, and license agreements, with payment obligations contingent on future milestones [141][142]. - The company is classified as an emerging growth company under the JOBS Act, allowing it to take advantage of certain reporting exemptions [146]. Inflation Impact - Inflation has not had a material effect on the company's consolidated financial statements, although it generally increases labor costs [154].